• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

DDD [ 3D Systems Corp ]
Last Trade 7.06 Date 8/6/2020
Change % 3.22 % Price Change 0.22
Open 6.93 52 Week High 12.56
High 7.06 52 Week Low 5.2
Low 6.71 Type stock
Volume 3308311 Average Volume 1904430
Prev Close 6.84 Stock Exchange NYSE
Bid 6.47 Ask 6.54
Bid Size 10 Ask Size 115
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 4.1107 Book Value Yield 0.601
Buy Back Yield CAPE Ratio
Cash Return 0.0349 Cash Flow per Share 0.3895
Cash Flow Yield 0.0569 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0819 EV/EBIT
EV/EBITDA EV / Free Cash Flow 31.707
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue 1.2925 EV / Total Asset 1.009
Expected Dividend Growth Rate Free Cash Flow per Share 0.2185
Free Caash Flow Ratio 31.304313 Free Cash Flow Yield 0.0319
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.663962 PB Ratio 10 Year Growth -0.065221
PB Ratio 3 Year Growth 2.184036 Cash Ratio 3 Year Average 1010.2457
Price to Cash Flow Ratio 17.562639 PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 88.274372 PE Ratio 10 Year Growth
PE Ratio 10 Year High 295.454545 PE Ratio 10 Year Low 18.367347
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth 0.001441
Free Cash Flow Ratio 3 Year Avg 83.145953 Price Change 1 Month 1.037936
Price to Cash Ratio 7.210104 Price / EBITDA
Price to Sales Ratio 1.276079 Price to Sales Ratio 10 Year Growth -0.074742
Price to Sales Ratio 3 Year Avg 1.859556 Price to Sales Ratio 5 Year Avg
Sale per Share 5.3602 Sales Yield 0.7837
Sustainable Growth Rate -0.1238 Tangible Book Value per Share 1.9068
Tangible Book Value per Share 3 year Avg 2.3317 Tangible Book Value per Share 5 year Avg 2.6063
Total Asset per Share 6.5926 Total Yield
Working Capital per Share 1.6922 Working Capital per Share 3 Year Avg 1.9207
Working Capital per Share 5 Year Avg 2.2875 Beta 1.756653
Company Profile

SCOLR Pharma, Inc., a pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold. The company is also developing IR Raloxifene for osteoporosis; ER Ondansetron, an anti-nausea drug; ER Phenylephrine a decongestant; and ER Niacin for cardiovascular disorders. In addition, it provides various formulation products for applications, including expectorant analgesic, sleep aid, cough-cold, decongestant and antihistamine, hypercholesterolemia and hypertriglyceridemia, pain management, beta-blockers, Ca Channel blockers, Alzheimer?s disease, schizophrenia/bi-polar, diabetes, motion sickness, asthma, and bronchodilator. SCOLR Pharma, Inc. has a strategic alliance with Perrigo Company of South Carolina, Inc. for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States; and research collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir for the treatment of seasonal and life threatening influenza. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Bothell, Washington.